333 related articles for article (PubMed ID: 27142582)
1. Safety of available treatment options for renal cell carcinoma.
Derosa L; Albiges L; Massard C; Loriot Y; Fizazi K; Escudier B
Expert Opin Drug Saf; 2016 Aug; 15(8):1097-106. PubMed ID: 27142582
[TBL] [Abstract][Full Text] [Related]
2. Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma.
Méndez-Vidal MJ; Martínez Ortega E; Montesa Pino A; Pérez Valderrama B; Viciana R
Cancer Metastasis Rev; 2012 Sep; 31 Suppl 1():S19-27. PubMed ID: 22821550
[TBL] [Abstract][Full Text] [Related]
3. Emerging Immunotargets in Metastatic Renal Cell Carcinoma.
Kucharczyk J; Matrana MR; Santoni M; Massari F; Scarpelli M; Cheng L; Lopez-Beltran A; Cascinu S; Montironi R; Holger M
Curr Drug Targets; 2016; 17(7):771-6. PubMed ID: 26648075
[TBL] [Abstract][Full Text] [Related]
4. Emerging growth factor receptor antagonists for the treatment of renal cell carcinoma.
Zahoor H; Rini BI
Expert Opin Emerg Drugs; 2016 Dec; 21(4):431-440. PubMed ID: 27690664
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma.
Albiges L; Fay AP; Xie W; Krajewski K; McDermott DF; Heng DY; Dariane C; DeVelasco G; Lester R; Escudier B; Choueiri TK
Eur J Cancer; 2015 Nov; 51(17):2580-6. PubMed ID: 26346135
[TBL] [Abstract][Full Text] [Related]
6. Targeted Therapy for Metastatic Renal Cell Carcinoma.
Afriansyah A; Hamid AR; Mochtar CA; Umbas R
Acta Med Indones; 2016 Oct; 48(4):335-347. PubMed ID: 28143997
[TBL] [Abstract][Full Text] [Related]
7. The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma.
Ornstein MC; Rini BI
Expert Rev Anticancer Ther; 2016 Jun; 16(6):577-84. PubMed ID: 27144724
[TBL] [Abstract][Full Text] [Related]
8. Emerging tyrosine kinase inhibitors for the treatment of renal cancer.
Iacovelli R; Albiges L; Escudier B
Expert Opin Emerg Drugs; 2015 Sep; 20(3):379-92. PubMed ID: 25982181
[TBL] [Abstract][Full Text] [Related]
9. Emerging therapeutic approaches in renal cell carcinoma.
Parekh H; Rini BI
Expert Rev Anticancer Ther; 2015; 15(11):1305-14. PubMed ID: 26376584
[TBL] [Abstract][Full Text] [Related]
10. Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations.
Puente J; García Del Muro X; Pinto Á; Láinez N; Esteban E; Arranz JÁ; Gallardo E; Méndez MJ; Maroto P; Grande E; Suárez C
Target Oncol; 2016 Apr; 11(2):129-41. PubMed ID: 26706236
[TBL] [Abstract][Full Text] [Related]
11. Pazopanib for the treatment of metastatic renal cell carcinoma.
Pick AM; Nystrom KK
Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
[TBL] [Abstract][Full Text] [Related]
12. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
[TBL] [Abstract][Full Text] [Related]
13. Impact of anti-angiogenic treatments on metastatic renal cell carcinoma.
Ainsworth NL; Lee JS; Eisen T
Expert Rev Anticancer Ther; 2009 Dec; 9(12):1793-805. PubMed ID: 19954291
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy.
Diamond E; Molina AM; Carbonaro M; Akhtar NH; Giannakakou P; Tagawa ST; Nanus DM
Crit Rev Oncol Hematol; 2015 Dec; 96(3):518-26. PubMed ID: 26321263
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction.
Gupta S; Parsa V; Heilbrun LK; Smith DW; Dickow B; Heath E; Vaishampayan U
Anticancer Drugs; 2011 Sep; 22(8):794-800. PubMed ID: 21799472
[TBL] [Abstract][Full Text] [Related]
16. Targeted treatment for metastatic renal cell carcinoma and immune regulation.
Laschos KA; Papazisis KT; Kontovinis LF; Kalaitzis C; Gianakopoulos S; Kortsaris AH; Touloupidis S
J BUON; 2010; 15(2):235-40. PubMed ID: 20658715
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy in metastatic renal cell carcinoma today? A systematic review.
Buti S; Bersanelli M; Sikokis A; Maines F; Facchinetti F; Bria E; Ardizzoni A; Tortora G; Massari F
Anticancer Drugs; 2013 Jul; 24(6):535-54. PubMed ID: 23552469
[TBL] [Abstract][Full Text] [Related]
18. Emerging oral VEGF inhibitors for the treatment of renal cell carcinoma.
Stitzlein L; Rao P; Dudley R
Expert Opin Investig Drugs; 2019 Feb; 28(2):121-130. PubMed ID: 30572736
[TBL] [Abstract][Full Text] [Related]
19. Emerging therapeutics in refractory renal cell carcinoma.
Koshkin VS; Rini BI
Expert Opin Pharmacother; 2016 Jun; 17(9):1225-32. PubMed ID: 27112171
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study.
Thiery-Vuillemin A; Theodore C; Jacobasch L; Schmitz J; Papandreou C; Guillot A; Emmanouilides C; Slimane K; Kelkouli N; Kim S; Nguyen Tan Hon T
Clin Genitourin Cancer; 2015 Jun; 13(3):231-8. PubMed ID: 25456838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
